|Articles|October 1, 2015
INC Research Receives iCardiac Site Certification
Advertisement
INC Research announced it is now certified to use the iCardiac Early Precision QT approach for evaluating the cardiac safety of new compounds in Phase I clinical development. INC’s use of iCardiac Early Precision QT technology in place, INC may be able to eliminate the need for a separate, dedicated Thorough QT (TQT) study, which can cost between $2 million and $5 million for its clients.
Read
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Outlines New Superiority Standard for Future CAR-T Approvals
2
Accelerating Clinical Trial Timelines with AI
3
When AI Learns to Speak Every Language: An eCOA Migration Study
4
ACT Brief: AI’s Impact on Trial Timelines, New Strategies in Obesity R&D, and Why Patient Support Needs a Clinical Backbone
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
